Needham Reiterates Buy on Mereo BioPharma Group, Maintains $7 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Gil Blum has reiterated a Buy rating on Mereo BioPharma Group (NASDAQ:MREO) and maintained a $7 price target.
August 13, 2024 | 5:58 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Gil Blum has reiterated a Buy rating on Mereo BioPharma Group (NASDAQ:MREO) and maintained a $7 price target.
The reiteration of a Buy rating and the maintenance of a $7 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100